Final Program [International AIDS Society (11th: 1996: Vancouver, Canada)]

WednsdayJul 10,199
VENUE ROOM TRACK SESSION NO. TIME I SESSION PATHWAYS
Plce1

Bay 9 }. 316 Track C: Epidemiology and Public Health
Exhibit Poster Discussion:
& Poster Feasibility of Vaccine Trials
Hall Moderators:
Suchada Chinaworapong, Thailand / Beryl Koblin, USA

We.C.210
ESTIMATION OF VACCINE EFFICACY FOR BOTH SUSCEPTIBILITY AND REDUCTION IN INFECTIOUSNESS FOR
PROPHYLACTIC HIV VACCINES
Longini, Ira M, Datta S, Halloran E. Emory University School of Public Health, Atlanta, GA, USA................................................................................................................................................................................................................................................
We.C.21 I
MOTIVATION FOR INTEREST AND REASONS FOR EXCLUSION IN A PHASE I/II HIV- I VACCINE TRIAL IN THAILAND
Chinaworapong, Suchada, Buapunth P Morgan P Chiu J,YutabootrY, Sontirat A, Khamboonruang C, Nitayaphan S, Michael RA. ARVEG
(AFRIMS RIHES Vaccine Evaluation Group), Bangkok and Chiang Mai,Thailand................................................................................................................................................................................................................................................
We.C.212
THE DECISION TO PARTICIPATE IN HIVVACCINE EFFICACY TRIALS:AN ASSESSMENT OF CHANGING WILLINGNESS
AMONG HOMOSEXUAL MEN
Bartholow Bradford N, MacQueen K, Douglas J, Buchbinder S, McKirnan D, Judson F. CDC, Atlanta, GA, USA................................................................................................................................................................................................................................................
We.C.213
CHALLENGES IN ASSESSING CLINICAL SAFETY OF HIV-I VACCINES
Ippolito,Tina MI, Francis DPI, Sricharoen M2, Punnee P2, Savarese B3, Fast P3, the NIAID AIDS Vaccine Clinical Trials Network.
'Genentech Inc., San Francisco, CA, USA; 2Mahidol University, Bangkok, Thailand; 3NIAID, Div. of AIDS, Bethesda, MD, USA................................................................................................................................................................................................................................................
We.C.214
FEASIBILITY OF AN HIV-I VACCINE EFFICACY TRIAL AMONG INJECTING DRUG USERS IN BANGKOK,THAILAND
Vaniyapongs,Thamnooni, Kampanartsanyakorn CI,Vanichseni SI,Apaiwongse 0', Raktham SI, Kasemsook RI,Wasi C2, Kitayaporn D2/3,
Mastro TD3/4, Des Jarlais DCs, Heyward WL6, Esparza J6. I Bangkok Metropolitan Administration; 2Mahidol University Bangkok;
3HIV/AIDS Collaboration, Nonthaburi,Thailand; 4CDC, Atlanta, GA; 5Beth Israel Medical Center, New York, NY USA; 6UNAIDS, o
Geneva, Switzerland.
We.C.215o
READINESS TO PARTICIPATE IN PREVENTIVE HIVVACCINE EFFICACY TRIALS IN HIGH-RISK POPULATIONS U
IN THE UNITED STATES
Koblin, Beryl A', Metzger D2, Sheon A3, Critchlow C4, Heagerty p4, the HIV Network for Efficacy Trials (HIVNET). INY Blood Center, n
New York, NY; 2University of Pennsylvania, Philadelphia, PA; 3NIAID/NIH, Bethesda, MD; 4University of Washington, Seattle, WA, USA.
0
O
U
O
U
0
a)
C

185